MAPT and Down syndrome: Mobley’s team in Down syndrome mice showed that BPN-15606 significantly reduced Aβ42 and Aβ40 levels; improved nerve growth factor signaling; reduced tau hyperphosphorylation, and corrected behavioral deficits, indicating its potential to delay or prevent AD onset in individuals with Down syndrome (Chen et al., 2024).